System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

François Aubin is an expert in Dermatology at Centre Hospitalier Universitaire de Besançon (France). As of October 2026, ScienceLeadR ranks François Aubin in the top 1% of experts worldwide for Skin Neoplasms, Sexually Transmitted Diseases and Melanoma. François Aubin has authored 855 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 7 of them ongoing. SLR score: 2,286 (community average: 125). How the SLR is computed.

LeadR Profile

François Aubin Centre Hospitalier Universitaire de Besançon France
2 286 ScienceLeadR Reputation 2286

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Immunology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

Hôpital Saint-Jacques (France, Besançon)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 855

Citations

Citations: 20 947 1st author: 63 Last author: 187 Unique author: 11

Main journals

Ann Dermatol Venereol 253
J Eur Acad Dermatol Venereol 51
Annales de dermatologie et de vénéréologie, FMC 42
Br J Dermatol 32
Eur J Dermatol 26

Best Journals

J Clin Oncol 9
Ann Oncol 6
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Targetoid-like necrotic plaque after low-molecular-weight heparin injection.
PMID 42569573 — injections, enoxaparin, heparin, heparin, low-molecular-weight		JAAD Case Rep20260
White Acanthotic Papules (WAP): An underrecognized entity that may correspond to the familial, non-photo-induced forms of idiopathic guttate hypomelanosis.
PMID 42468070 — hypopigmentation, sexually transmitted diseases, dermatology		Ann Dermatol Venereol20260
Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).
PMID 42372635 — melanoma, cohort studies, therapeutics		Eur J Cancer20260
Invasive group A Streptococcal infections in Franche-Comté, France (2022-2023).
PMID 42183688 — skin, mortality, streptococcal infections, skin diseases, beta-lactams, therapeutics, infections, child, lactams		Eur J Dermatol20260
Photoinduced granulomatous drug reaction related to lamotrigine.
PMID 42183094 — granuloma, lamotrigine, pharmaceutical preparations, drug eruptions		JAAD Case Rep20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8

By phase:

N/A 12
Phase 3 9
Phase 2 6
Phase 4 2
Phase 1 1

By status:

Completed 10
Active not recruiting 7
Recruiting 7
Unknown 3
Terminated 2
Not yet recruiting 1

By type:

Interventional 21
Observational 9

By Monocentric/Multicentric:

monocentric 12
multicentric2to4 0
multicentric5to9 1
multicentricup10 17

Main Topics

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
VAC WARTS
2024-513671-40-00 — vaccines, warts, therapeutics		Phase 3Recruiting2022
This Study is a Non interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803 — registries, dermatitis, adolescent, therapeutics, dermatitis, atopic		N/ARecruiting2025
Dupilumab step down strategy to maintain remission in adult and adolescents patients with atopic dermatitis a non inferiority randomized trial
2022-501179-23-00 — dermatitis, adolescent, dermatitis, atopic		Phase 4Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS